Navigation Links
Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies
Date:11/6/2013

London (PRWEB) November 06, 2013

MCD Group continuously researches and monitors emerging drug delivery technologies and has compiled this report to profile some of the innovative developments at younger, emerging companies. The report focuses on start-ups and smaller companies that tend to be less well known, but are expected to gain momentum as they advance their technologies and produce significant clinical data. All of the companies profiled have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their technologies.

The report features profiles of 62 companies, a majority of which were founded in the past five years. Most are located in the United States; however a few profiled companies are based in Canada, Europe, and Australia. Approximately 50% of the companies are affiliated with a University, and ten companies have initiated human clinical trials.

Collectively, the emerging companies profiled in this report are focused on 11 different therapeutic categories. Oncology is the leading focus among companies investigated, and approximately 25 percent of the companies profiled are developing proprietary technologies designed to improve delivery of macromolecules/biologics. Another 25 percent of the companies are focused on novel delivery devices, ranging from inhalation and nasal devices, to more patient-friendly injectable systems. All of the companies investigated are developing technologies that could potentially transform drug delivery in one or more therapeutic areas.

For each company profiled, the following information is provided:

•Detailed Technology Description
•Development Status / Pipeline Products
•Patents and Publications
•Partnership and Funding Opportunities
•Business Development & Licensing Contact

Examples of Technologies Presented

•Mini-pump for subcutaneous delivery of IV medications
•Targeted nanoparticle micelles
•Antibody-targeted liposomes
•Abuse-deterrent delivery system
•Dry powder particle processing technology
•Oral capsule technology for biologics
•Nanovesicle delivery system for delivery across the blood-brain barrier
•Timed-release intra-ocular implant device
•Non-invasive aerosol device for brain drug delivery
•Extracellular drug conjugate technology
•Nanoparticles and novel device for CNS and inner ear drug delivery
•Next-generation auto-injector technology
•Nanopolymer drug conjugates
•Microneedle patch system
•Pocket-sized ultrasound delivery device
•Biodegradable, topical drug patch

Sample of Companies Profiled

•Aquarius Biotechnologies
•LaserLeap
•Convoy Therapeutics
•Orbis Biosciences
•Corinthian Ophthalmic
•Qrono, Inc.
•Entrega, Inc.
•scPharmaceuticals
•HylaPharm
•TheraTarget
•Inspiro Medical
•ZetrOZ, LLC

Reasons to Buy

•Identify early stage delivery technologies that will potentially "enable" the delivery of your therapeutic compound
•Learn about investment opportunities with emerging companies, to gain access to promising, early stage technologies
•Identify novel drug delivery formulations available for partnering, to enhance your product portfolio

Table of Contents

Executive Summary

Figure 1: Featured Companies by Year Founded
Figure 2: Featured Early Stage Technologies by Delivery Route
Table 1: Sample of Emerging Parenteral DDS Companies
Table 2: Sample of Emerging Delivery Devices in Development
Table 3: Ten Novel Pipeline Products of DDS Start-ups
Table 4: Emerging Companies by Therapeutic Focus

Company Profiles

ABsize, Inc.
Affinity Therapeutics, LLC
AiroMedica, LLC
AlignBioscience Laboratory, LLC
Alitair Pharmaceuticals, Inc.
Aquarius Biotechnologies
Axxia Pharmaceuticals, LLC
Blend Therapeutics
Centrose, LLC
Civitas Therapeutics
Clearside Biomedical, Inc.
Convoy Therapeutics
Corinthian Ophthalmic, Inc.
Cristal Delivery, B.V.
Dance Pharma
DLVR Therapeutics
Ekteino Laboratories, Inc.
EnduRx Pharmaceuticals, Inc.
Engineered BioPharmaceuticals, Inc.
Entrega, Inc.
Extend Biosciences, Inc.
FluGen, Inc.
GrayBug, LLC
HylaPharm
Impel Neuropharma
Inspirion Delivery Technologies, LLC
Inspiro Medical, Ltd.
Intensity Therapeutics, Inc.
iVeena, LLC
KAER Biotherapeutics
Kala Pharmaceuticals, Inc.
Keystone Nano
LaserLeap Technologies
Lauren Sciences, LLC
LyoGo, LLC
Lypro Biosciences, Inc.
NanoMedical Systems, Inc.
NanoSmart Pharmaceuticals, Inc.
On Demand Therapeutics, Inc.
Orbis Biosciences, Inc.
OtoMagnetics & Weinberg Medical Physics
Oval Medical Technologies
PhaseRx
PolyActiva Pty, Ltd.
PolyPid, Ltd.
ProLynx, LLC
Prometheon Pharma, LLC
ProSolus Pharma, LP
Prosonix, Ltd.
Quiet Therapeutics
Qrono, Inc.
Ratio, Inc.
Respira Therapeutics, Inc.
scPharmaceuticals, LLC
SipNose, Ltd.
Solstice Biologics, LLC
SpherIngenics, Inc.
TheraTarget
Vaxxas
Versartis, Inc.
Xeris Pharmaceuticals, Inc.
ZetrOZ, LLC

Read the full report:

Emerging Drug Delivery Technologies, Profiles of Start-ups and Early-Stage Companies

http://www.reportbuyer.com/pharma_healthcare/drug_delivery/emerging_drug_delivery_technologies_profiles_start_ups_early_stage_companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com/

Read the full story at http://www.prweb.com/releases/2013/11/prweb11307459.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New Treatments Emerging from Immune and Inflammatory Disease R&D Pipelines
2. CDC Warns of Another Emerging Tick-Borne Threat
3. New Immune-Deficiency Illness Emerging in East Asia
4. Expanding database enables discoveries in emerging field of metabolomics
5. CWRUs Maxwell J. Mehlmans book examines issues emerging in genetic engineering
6. Queens scientist is named Emerging Scientist 2012
7. Chicago Hat Designer Tonya Gross Selected by Online Retailer Zappos.com for 2013 Emerging Designer Program
8. NIH scientists reflect on gains in emerging infectious disease awareness, research and response
9. Emerging cancer drugs may drive bone tumors
10. OLEV selected as 1 of 10 emerging technologies in 2013 by World Economic Forum
11. Emerging SARS-Like Virus Well-Suited to Attack Humans: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... The ... its fully redesigned website, which launched October 17, 2016, features comprehensive information regarding ... and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments ...
(Date:12/7/2016)... , ... December 07, 2016 , ... Delete® - Tattoo ... Time For The Holiday Party Season. Save Up To 33% Off Botox® and Juvederm® ... is providing the Phoenix Valley with Delightful Deals on Botox® and Juvederm® ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live From won ... year’s best in pioneering, inventive, and ultimately successful projects undertaken by the media ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors to create ... Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book ... Editors can select from a variety of flip book animations. In Addition, users can ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 7, 2016  The Corporate Whistleblower Center ... call them anytime at 866-714-6466 if they possess proof ... more drugs. Aside from the innocent patients frequently being the ... because often-times these practices target Medicare recipients or the elderly. ... ...
(Date:12/7/2016)... READING, Mass. , Dec. 7, 2016 /PRNewswire/ ... and Trace Network for connecting the Life Sciences ... the global marketplace, today announced that Tjoapack has ... European pharmaceutical manufacturing customers comply with the rapidly ... Chain Security Act (DSCSA) in 2017 and the ...
(Date:12/7/2016)... 7, 2016 According to responses from U.S. oncologists ... (38%) of patients with non-small cell lung cancer (NSCLC), treatment ... (EGFR) genetic mutation status. The findings of the survey were ... #6067 #P3.02b ) at the 2016 World Conference on ... The survey results revealed an overall high rate ...
Breaking Medicine Technology: